In fact, there is a growing body of evidence that shows how the use of ICIs could be more beneficial in PCa patients belonging to a specific sub-group characterised by high PD-L1 tumour expression or high tumour mutational burden [10]. Here, CD274 is linked to posterior cortical atrophy.